TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11396393

Group type: EXPERIMENTAL
Intervention: Alcoholics (after one week of forced abstinence)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Alcoholics (on admission)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Alcoholics
Number of subjects: 37

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 37
Study: 9420391

Group type: EXPERIMENTAL
Intervention: 5 ml/kg plain water orally 3 hours before surgery
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 5 ml/kg plain water and 2 mg/kg of ranitidine orally 3 hours before surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (fasted from midnight)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fluid treated patients (groups II and III)
Number of subjects: 75
Study: 8127947

Group type: EXPERIMENTAL
Intervention: Active TRP depletion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham TRP depletion
Number of subjects: 11
Study: 3290713

Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI) with lymphocyte counts < 900/mm3
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI) with lymphocyte counts > 900/mm3
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 48
Study: 30911906

Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (50 mg) with high-fat meal consumption 30 min before administration
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (50 mg) sprinkled on applesauce
Number of subjects: 16

Group type: COMPARATOR
Intervention: SHP465 mixed amphetamine salts (50 mg) fasting (reference treatment)
Number of subjects: 16
Study: 28755607

Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg daily)
Number of subjects: 70
Study: 26925901

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blind corticosteroid injection
Number of subjects: 40
Study: 22646219

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 150 mg/day
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 21529923

Group type: EXPERIMENTAL
Intervention: Filtek Supreme
Number of subjects: 35

Group type: COMPARATOR
Intervention: Z100
Number of subjects: 35
Study: 19909462

Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 315

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 315
Study: 20827547

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 250

Group type: COMPARATOR
Intervention: Alendronate 70 mg orally once weekly
Number of subjects: 250

Group type: COMPARATOR
Intervention: Denosumab compared to Alendronate
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 250

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 250
Study: 15769239

Group type: EXPERIMENTAL
Intervention: Leaders in a positive mood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leaders in a negative mood
Number of subjects: 0
Study: 12358334

Group type: EXPERIMENTAL
Intervention: Lipid extract of New Zealand green-lipped mussel (Lyprinol)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 9655733

Group type: EXPERIMENTAL
Intervention: High-dose prednisone (60 mg/d for 1 month, tapered to 40 mg/d for the second month, then 40 mg every other day during the third month)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Colchicine (0.6-1.2 mg/d, as tolerated)
Number of subjects: 26

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 26
Study: 7649652

Group type: EXPERIMENTAL
Intervention: Previous back injury
Number of subjects: 175

Group type: COMPARATOR
Intervention: No previous back injury
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Symptomatic cases attributing symptoms to injury
Number of subjects: 175

Group type: COMPARATOR
Intervention: Comparison of groups attributing symptoms to injury vs. no injury
Number of subjects: 175
Study: 2665493

Group type: EXPERIMENTAL
Intervention: 100 IU oxytocin administered into the umbilical veins
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 870096

Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (18 mg of delta‐9‐THC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo marijuana cigarette (0.05 mg of delta‐9‐THC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo marijuana smoking
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Marijuana smoking
Number of subjects: 10
Study: 11375826

Group type: EXPERIMENTAL
Intervention: Coadministration of propofol and small-dose ketamine (propofol 33 +/- 13 microg x kg(‐1) x min(‐1) and ketamine 3.7 +/- 1.5 microg x kg(‐1) x min(‐1))
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Coadministration of propofol and small-dose ketamine
Number of subjects: 39
Study: 31500605

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) + Androgen deprivation therapy (ADT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study: 29490289

Group type: COMPARATOR
Intervention: OC + placebo
Number of subjects: 81

Group type: COMPARATOR
Intervention: LNG OC + placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: OC + DHEA
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: DHEA co-administration
Number of subjects: 81
Study: 26952317

Group type: EXPERIMENTAL
Intervention: Lysozyme hydrochloride (LYS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23888869

Group type: EXPERIMENTAL
Intervention: Temporally synchronized audio-visual components
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Temporally desynchronized audio-visual components (366, 500, or 666 ms)
Number of subjects: 120
Study: 22261795

Group type: EXPERIMENTAL
Intervention: C-MAC video laryngoscope
Number of subjects: 300

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 300
Study: 21180218

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg intravaginally)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Dinoprostone (0.5 mg intracervically)
Number of subjects: 66
Study: 17585117

Group type: EXPERIMENTAL
Intervention: Inhaled human [rDNA Origin] insulin
Number of subjects: 0
Study: 15172365

Group type: EXPERIMENTAL
Intervention: CMC‐001 (0.8 g MnCl2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CMC‐001 (1.6 g MnCl2)
Number of subjects: 12
Study: 12231595

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 9655270

Group type: EXPERIMENTAL
Intervention: 1 g cefazolin intravenously every 8 hours
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo intravenously every 8 hours
Number of subjects: 139
Study: 7815722

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Drip Infusion Cholecystography (DIC)
Number of subjects: 80
Study: 2673337

Group type: EXPERIMENTAL
Intervention: Repeated external cephalic version
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no version attempted)
Number of subjects: 180
Study: 788993

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Aspirin 1200 mg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 30734629

Group type: EXPERIMENTAL
Intervention: Fentanyl-soaked Merocel® packing (50 mcg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Saline-soaked packing
Number of subjects: 65
Study: 28124405

Group type: EXPERIMENTAL
Intervention: Educational video intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Comparison group (no educational video)
Number of subjects: 90
Study: 25246602

Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 3

Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 3

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 3
Study: 22813235

Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: BRV 150 mg/day
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 21950702

Group type: EXPERIMENTAL
Intervention: 1 mg of Avastin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.3 mg Macugen
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sequential treatment (1 mg Avastin followed by 0.3 mg Macugen)
Number of subjects: 48
Study: 18440952

Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine-midazolam-propofol (KMP)
Number of subjects: 209

Group type: COMPARATOR
Intervention: sufentanil-midazolam-propofol (SMP)
Number of subjects: 209
Study: 16571390

Group type: EXPERIMENTAL
Intervention: Visual biofeedback
Number of subjects: 18

Group type: COMPARATOR
Intervention: No visual feedback
Number of subjects: 18
Study: 12436326

Group type: EXPERIMENTAL
Intervention: Phentolamine test
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sympathetic nerve blockade
Number of subjects: 29
Study: 10600092

Group type: EXPERIMENTAL
Intervention: rhIGF‐1 0.01 mg/kg/hour and daily subcutaneous doses of rhGH 0.05 mg/kg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 23
Study: 7864425

Group type: EXPERIMENTAL
Intervention: esmolol, 1.3 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: esmolol, 4.4 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: labetalol, 0.13 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: labetalol, 0.44 mg/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: no drug
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: esmolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: esmolol and labetalol
Number of subjects: 18
Study: 2167806

Group type: EXPERIMENTAL
Intervention: Intralipid (10%) and heparin (Lipid)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8
Study: 6796270

Group type: EXPERIMENTAL
Intervention: Chlordesmethyldiazepam 2 mg (CDDZ2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlordesmethyldiazepam 1 mg (CDDZ1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30441483

Group type: EXPERIMENTAL
Intervention: Extra-Trees algorithm for supervised classification
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Error Correcting Output Codes (ECOC) approach
Number of subjects: 9
Study: 28062091

Group type: EXPERIMENTAL
Intervention: Person-centred care intervention group
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199
Study: 26670971

Group type: EXPERIMENTAL
Intervention: TTFields plus temozolomide
Number of subjects: 695

Group type: COMPARATOR
Intervention: Temozolomide alone
Number of subjects: 695
Study: 24176132

Group type: EXPERIMENTAL
Intervention: Gender dialogue groups added to group savings program
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Gender dialogue groups added to group savings program (high adherence)
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Gender dialogue groups added to group savings program (low adherence)
Number of subjects: 934

Group type: COMPARATOR
Intervention: Group savings only (control)
Number of subjects: 934
Study: 20857093

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24692816

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Candesartan (8-12 mg/d)
Number of subjects: 20
Study: 16793604

Group type: EXPERIMENTAL
Intervention: Ketamine (0.25 mg/kg bolus followed by 0.5 mg.kg(‐1).h(‐1) infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (saline of the same amount)
Number of subjects: 20
Study: 12658084

Group type: EXPERIMENTAL
Intervention: Topical azelastine 0.02%
Number of subjects: 63

Group type: COMPARATOR
Intervention: Topical mitomycin C (0.2 mg/10 mL)
Number of subjects: 63
Study: 10726221

Group type: EXPERIMENTAL
Intervention: Reminder sticker and patient education sign in each examining room
Number of subjects: 778

Group type: COMPARATOR
Intervention: Patient education sign only
Number of subjects: 778

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 778
Study: 9143790

Group type: EXPERIMENTAL
Intervention: Blood pressure screening intervention
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Follow-up after withdrawal from therapy
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Randomization to screening
Number of subjects: 6000
Study: 7515115

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Dextran
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study: 2954024

Group type: EXPERIMENTAL
Intervention: Nebulized fenoterol alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Fenoterol plus ipratropium bromide
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Fenoterol plus corticosteroids
Number of subjects: 94

Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 94
Study: 29265884

Group type: EXPERIMENTAL
Intervention: Xbox Kinect exergames played twice weekly for 8 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual activities (Control)
Number of subjects: 65
Study: 27582297

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise training (PRET)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonprogressive exercise intervention, modified Fitness Counts (mFC)
Number of subjects: 48
Study: 23809507

Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) without IFG
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: IGT and IFG
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Indeterminate glucose tolerance (INDET)
Number of subjects: 1093
Study: 23473266

Group type: EXPERIMENTAL
Intervention: Minimally invasive percutaneous plate osteosynthesis (MIPPO)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Traditional open reduction and internal fixation (ORIF)
Number of subjects: 94
Study: 20711070

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 960

Group type: COMPARATOR
Intervention: Chlorhexidine and silver sulfadiazine
Number of subjects: 960
Study: 18190664

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Buprenorphine maintenance treatment
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Opioid treatment exposure longer than 7 days
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Older participants randomized to buprenorphine treatment
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Aboriginal or Torres Strait Islander participants
Number of subjects: 405
Study: 15864409

Group type: EXPERIMENTAL
Intervention: Electrolytic iron (A-131)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Electrolytic iron (Electrolytic)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Carbonyl iron (Ferronyl)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: H-reduced iron (AC-325)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: H-reduced iron (Hi-Sol)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Carbonyl iron (CF)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reduced iron (Atomet 95SP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ferrous sulfate (FeSO4)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Electrolytic iron with 50 mg ascorbic acid (AA)
Number of subjects: 48
Study: 12039500

Group type: EXPERIMENTAL
Intervention: Amplatzer septal occluder (ASO) for device closure
Number of subjects: 596

Group type: COMPARATOR
Intervention: Surgical closure
Number of subjects: 596
Study: 9808595

Group type: EXPERIMENTAL
Intervention: gemfibrozil 1200 mg/d
Number of subjects: 372

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 372
Study: 7498447

Group type: COMPARATOR
Intervention: Tamm-Horsfall glycoproteins from healthy probands
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tamm-Horsfall glycoproteins from recurrent calcium oxalate renal stone formers
Number of subjects: 2
Study: 2566048

Group type: EXPERIMENTAL
Intervention: Oral cyclosporin 10 mg/kg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colchicine 1 mg orally per day
Number of subjects: 0
Study: 794686

Group type: EXPERIMENTAL
Intervention: Tibezonium iodide tablets
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Tibezonium iodide bubble-gums
Number of subjects: 160
Study: 6111742

Group type: EXPERIMENTAL
Intervention: Analgesic drugs
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 70
Study: 30732506

Group type: EXPERIMENTAL
Intervention: AST-120 (KREMEZIN®)
Number of subjects: 0
Study: 28651370

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle change with goals of weight reduction and 150 min/wk of moderate intensity exercise
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Metformin administered 850 mg twice a day
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 27737719

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) alone
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) with educational outreach
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) with shared learning opportunities
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) with both educational outreach and shared learning opportunities
Number of subjects: 250
Study: 24650695

Group type: EXPERIMENTAL
Intervention: Partial Hepatectomy (PH)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Transcatheter Arterial Chemoembolization (TACE)
Number of subjects: 173
Study: 22007645

Group type: EXPERIMENTAL
Intervention: Higher serum aldosterone
Number of subjects: 344
Study: 20079208

Group type: EXPERIMENTAL
Intervention: HD‐DXM + RM group (40 mg/d of dexamethasone in a 4‐day pulse every 14 days for 3 cycles + 0.035 mg x kg(‐1) x d(‐1) for maintenance)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HD‐DXM + SM group (40 mg/d of dexamethasone in a 4‐day pulse every 14 days for 3 cycles + 0.035 mg x kg(‐1) x d(‐1) only when platelet count < 20 x 10(9)/L)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (routine dosage of prednisone)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HD‐DXM + RM group
Number of subjects: 45

Group type: COMPARATOR
Intervention: HD‐DXM + SM group and Control group
Number of subjects: 45
Study: 17207801

Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching
Number of subjects: 159

Group type: COMPARATOR
Intervention: Hatching with acidified medium
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Day 5 transfers
Number of subjects: 159
Study: 15080375

Group type: EXPERIMENTAL
Intervention: 1 ml/kg of alcohol for 7 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control drink for 3 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Alcohol restriction for 1 week
Number of subjects: 14
Study: 11993223

Group type: EXPERIMENTAL
Intervention: Mini-thoracolaparotomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional thoracolaparotomy
Number of subjects: 30
Study: 9617979

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 25
Study: 7799496

Group type: EXPERIMENTAL
Intervention: Screening mammography in women aged 50 to 74 years
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Screening mammography in women aged 40 to 49 years
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Two-view mammography in women aged 40 to 49 years
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: One-view mammography in women aged 40 to 49 years
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Studies with 7 to 9 years of follow-up in women aged 40 to 49 years
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Studies with 10 to 12 years of follow-up in women aged 40 to 49 years
Number of subjects: 13
Study: 2649121

Group type: EXPERIMENTAL
Intervention: Exeter cement gun
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hand insertion of cement
Number of subjects: 21
Study: 55895

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (400 mg daily) for 1 week before and 1 week after 5 mCi therapy dose of 131I
Number of subjects: 16

Group type: COMPARATOR
Intervention: 5 mCi of 131I without lithium therapy
Number of subjects: 16
Study: 31662352

Group type: EXPERIMENTAL
Intervention: ICE training intervention (1-day training session on patient-centred communication)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (usual consultations without ICE training)
Number of subjects: 48
Study: 29156912

Group type: EXPERIMENTAL
Intervention: Prophylactic dexamethasone
Number of subjects: 81

Group type: COMPARATOR
Intervention: No prophylactic dexamethasone (Control)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: High-risk patient group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Multivariable model for pain flare
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Multivariable model for dexamethasone response
Number of subjects: 81